Back to Top

Informing, inspiring, and advancing global innovation to support a healthy, sustainable future

For Immediate Release

Interleukin-27: Can a Cytokine with Both Pro- and Anti-Inflammatory Activity Make a Good Drug Target?

Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com

Mary Ann Liebert, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com

New Rochelle, NY, October 20, 2014—Interleukin-27 (IL-27), a member of the interleukin family of cytokines that help regulate the immune system, has a mainly anti-inflammatory role in the body, and its dysfunction has been implicated in autoimmune diseases such as multiple sclerosis and Crohn’s disease. More recently, IL-27’s proinflammatory activity and role in chronic inflammatory diseases is becoming increasingly clear, and a new Review article that explores the potential to target a range of diseases that share common IL-27-activated mechanisms is presented in Journal of Interferon & Cytokine Research (JICR), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the JICR website until November 20, 2014.

Christopher Wynick, Carlene Petes, and Katrina Gee, Queen’s University, Kingston, Canada, explain how IL-27 can contribute to the control of both anti- and proinflammatory responses depending on the predominant type of immune response elicited in the body, the disease type, and the disease severity. They focus primarily on the proinflammatory activity of the cytokine in the article “Interleukin-27 Mediates Inflammation During Chronic Disease.”

“IL-27 is emerging as a significant determinant of the character of inflammatory response and this review provides an important perspective,” says Co-Editor-in-Chief Thomas A. Hamilton, PhD, Chairman, Department of Immunology, Cleveland Clinic Foundation, Ohio.

About the Journal
Journal of Interferon & Cytokine Research (JICR), led by Co-Editors-in-Chief Ganes C. Sen, PhD, Chairman, Department of Molecular Genetics, Cleveland Clinic Foundation, and Thomas A. Hamilton, PhD, Chairman, Department of Immunology, Cleveland Clinic Foundation, is an authoritative peer-reviewed journal published monthly online with Open Access options and in print that covers all aspects of interferons and cytokines from basic science to clinical applications. JICR is an official journal of the International Cytokine & Interferon Society. Complete tables of content and a sample issue may be viewed on the Journal of Interferon & Cytokine Research website.

About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Viral Immunology, AIDS Research and Human Retroviruses, and DNA and Cell Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com